转移性去势抵抗性前列腺癌患者尿液外泌体ARV7 检测
核心信息
- 论文英文标题: Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients
- 期刊: Transl Androl Urol
- 发表年份: 2022
- DOI: 10.21037/tau-21-1136
- PMID/PMCID: 35280667; PMC8899142
研究概览
The present study showed that the detection of urine-derived exosomal AR-V7 provides a sensitive and feasible clinical workflow. We performed a non-invasive urine-derived exosomal AR-V7 analysis of mCRPC patients.
核心发现
Urine is the ideal biological sample for exosome separation and AR full-length analysis.
4% (11 of 34) of the mCRPC patients' urine samples.
研究设计
A total of 34 mCRPC patients were recruited including 16 patients treated with abiraterone (ABI) with stable prostate-specific antigen (PSA)/radiograph response (the ABI-Sta group) and 18 were resistant to abiraterone (the ABI-Res group).
Urine was collected from patients and healthy control patients for the analysis.
Exosomal ribonucleic acid was isolated from urine.
Echo Biotech 角色
Echo Biotech's specific contribution should be verified from the full text or internal project record.
关联平台: To Be Verified
关联服务与能力: Role Not Identified
关联产品或试剂: 无明确产品引用
参考文献
原始论文: Urinary exosome-based androgen receptor-variant 7 detection in metastatic castration-resistant prostate cancer patients Transl Androl Urol. 2022. DOI: 10.21037/tau-21-1136. PMID/PMCID: 35280667; PMC8899142.